{"id":"W4396804144","doi":"10.1097/mnm.0000000000001858","title":"A phase 2, single-arm trial evaluating 131I-PSMA-1095 targeted radioligand therapy for metastatic castration-resistant prostate cancer","year":2024,"lang":"en","type":"article","venue":"Nuclear Medicine Communications","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Prostate cancer; Tolerability; Clinical endpoint; Internal medicine; Adverse effect; Oncology; Enzalutamide; Phases of clinical research; Urology; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009200797,0.0002586569,0.0004961947,0.0002737046,0.0005426671,0.00008898729,0.0003507087,0.00006925903,0.0005975859],"category_scores_gemma":[0.0003698094,0.0001815338,0.0001604005,0.0006001504,0.0004538877,0.0001552553,0.00006840375,0.0004064906,0.00002243462],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003303363,"about_ca_system_score_gemma":0.0007136425,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002250051,"about_ca_topic_score_gemma":0.00005646285,"domain_scores_codex":[0.9978838,0.0002079795,0.000611406,0.0003880135,0.0005054954,0.0004032855],"domain_scores_gemma":[0.9974939,0.0006740573,0.0001264798,0.001077652,0.0003909162,0.0002369644],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0803744,0.00687924,0.0000242756,0.0008350497,0.002201909,0.00006691025,0.02260367,0.000009838402,0.5629849,0.003280793,0.03515532,0.2855837],"study_design_scores_gemma":[0.3411089,0.05581258,0.0001440789,0.002948856,0.002090981,0.00007564033,0.004594609,0.04575294,0.004387411,0.00162627,0.5408069,0.0006507681],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.719362,0.1323233,0.0001690675,0.1279957,0.001083264,0.01258228,0.0005259967,0.000637313,0.005321016],"genre_scores_gemma":[0.9793376,0.01020927,0.004894902,0.0007106678,0.0005463795,0.001569263,0.000842796,0.0001230835,0.001766072],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5585974,"threshold_uncertainty_score":0.7402735,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2433899594419136,"score_gpt":0.4876039271628204,"score_spread":0.2442139677209067,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}